Literature DB >> 19876042

Targeting protein kinases in central nervous system disorders.

Laura K Chico1, Linda J Van Eldik, D Martin Watterson.   

Abstract

Protein kinases are a growing drug target class in disorders in peripheral tissues, but the development of kinase-targeted therapies for central nervous system (CNS) diseases remains a challenge, largely owing to issues associated specifically with CNS drug discovery. However, several candidate therapeutics that target CNS protein kinases are now in various stages of preclinical and clinical development. We review candidate compounds and discuss selected CNS protein kinases that are emerging as important therapeutic targets. In addition, we analyse trends in small-molecule properties that correlate with key challenges in CNS drug discovery, such as blood-brain barrier penetrance and cytochrome P450-mediated metabolism, and discuss the potential of future approaches that will integrate molecular-fragment expansion with pharmacoinformatics to address these challenges.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19876042      PMCID: PMC2825114          DOI: 10.1038/nrd2999

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  192 in total

1.  Characteristic physical properties and structural fragments of marketed oral drugs.

Authors:  Michal Vieth; Miles G Siegel; Richard E Higgs; Ian A Watson; Daniel H Robertson; Kenneth A Savin; Gregory L Durst; Philip A Hipskind
Journal:  J Med Chem       Date:  2004-01-01       Impact factor: 7.446

Review 2.  Alzheimer's disease pathogenesis and therapeutic interventions.

Authors:  M S Parihar; Taruna Hemnani
Journal:  J Clin Neurosci       Date:  2004-06       Impact factor: 1.961

3.  p38 kinase is activated in the Alzheimer's disease brain.

Authors:  K Hensley; R A Floyd; N Y Zheng; R Nael; K A Robinson; X Nguyen; Q N Pye; C A Stewart; J Geddes; W R Markesbery; E Patel; G V Johnson; G Bing
Journal:  J Neurochem       Date:  1999-05       Impact factor: 5.372

4.  Wide therapeutic time window for fasudil neuroprotection against ischemia-induced delayed neuronal death in gerbils.

Authors:  Shin-ichi Satoh; Yoshinori Toshima; Ichiro Ikegaki; Masakazu Iwasaki; Toshio Asano
Journal:  Brain Res       Date:  2006-11-22       Impact factor: 3.252

5.  Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

Authors:  Angelo O Rosa; Manuella P Kaster; Ricardo W Binfaré; Susana Morales; Ester Martín-Aparicio; Maria Luisa Navarro-Rico; Ana Martinez; Miguel Medina; Antonio G García; Manuela G López; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-06-25       Impact factor: 5.067

6.  CEP-1347 reduces mutant huntingtin-associated neurotoxicity and restores BDNF levels in R6/2 mice.

Authors:  Barbara L Apostol; Danielle A Simmons; Chiara Zuccato; Katalin Illes; Judit Pallos; Malcolm Casale; Paola Conforti; Catarina Ramos; Margaret Roarke; Satish Kathuria; Elena Cattaneo; J Lawrence Marsh; Leslie Michels Thompson
Journal:  Mol Cell Neurosci       Date:  2008-04-24       Impact factor: 4.314

7.  SP600125, a new JNK inhibitor, protects dopaminergic neurons in the MPTP model of Parkinson's disease.

Authors:  Wenya Wang; Leyu Shi; Yuanbin Xie; Chi Ma; Wenming Li; Xingwen Su; Shoujian Huang; Ruzhu Chen; Zhenyu Zhu; Zixu Mao; Yifan Han; Mingtao Li
Journal:  Neurosci Res       Date:  2004-02       Impact factor: 3.304

8.  Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.

Authors:  Amrita V Kamath; Jian Wang; Francis Y Lee; Punit H Marathe
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-11       Impact factor: 3.333

Review 9.  The GSK3 hypothesis of Alzheimer's disease.

Authors:  Claudie Hooper; Richard Killick; Simon Lovestone
Journal:  J Neurochem       Date:  2007-12-18       Impact factor: 5.372

Review 10.  Glycogen synthase kinase 3: a key regulator of cellular fate.

Authors:  J E Forde; T C Dale
Journal:  Cell Mol Life Sci       Date:  2007-08       Impact factor: 9.261

View more
  80 in total

1.  A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes.

Authors:  Jagat C Borah; Shiraz Mujtaba; Ioannis Karakikes; Lei Zeng; Michaela Muller; Jigneshkumar Patel; Natasha Moshkina; Keita Morohashi; Weijia Zhang; Guillermo Gerona-Navarro; Roger J Hajjar; Ming-Ming Zhou
Journal:  Chem Biol       Date:  2011-04-22

Review 2.  Natural products as a source of Alzheimer's drug leads.

Authors:  Philip Williams; Analia Sorribas; Melanie-Jayne R Howes
Journal:  Nat Prod Rep       Date:  2010-11-12       Impact factor: 13.423

3.  Mechanisms of regulation of oligodendrocyte development by p38 mitogen-activated protein kinase.

Authors:  Li-Jin Chew; William Coley; Ying Cheng; Vittorio Gallo
Journal:  J Neurosci       Date:  2010-08-18       Impact factor: 6.167

4.  The p38 MAP Kinase Family as Regulators of Proinflammatory Cytokine Production in Degenerative Diseases of the CNS.

Authors:  Adam D Bachstetter; Linda J Van Eldik
Journal:  Aging Dis       Date:  2010-09-24       Impact factor: 6.745

Review 5.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

Review 6.  Fyn in Neurodevelopment and Ischemic Brain Injury.

Authors:  Renatta Knox; Xiangning Jiang
Journal:  Dev Neurosci       Date:  2015-02-17       Impact factor: 2.984

7.  A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

Authors:  Rachel M Sammons; Nicole A Perry; Yangmei Li; Eun Jeong Cho; Andrea Piserchio; Diana P Zamora-Olivares; Ranajeet Ghose; Tamer S Kaoud; Ginamarie Debevec; Chandra Bartholomeusz; Vsevolod V Gurevich; Tina M Iverson; Marc Giulianotti; Richard A Houghten; Kevin N Dalby
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

8.  Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3.

Authors:  Martin Golkowski; Gayani K Perera; Venkata Narayana Vidadala; Kayode K Ojo; Wesley C Van Voorhis; Dustin J Maly; Shao-En Ong
Journal:  Mol Omics       Date:  2018-02-12

9.  Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Authors:  Val S Goodfellow; Colin J Loweth; Satheesh B Ravula; Torsten Wiemann; Thong Nguyen; Yang Xu; Daniel E Todd; David Sheppard; Scott Pollack; Oksana Polesskaya; Daniel F Marker; Stephen Dewhurst; Harris A Gelbard
Journal:  J Med Chem       Date:  2013-10-03       Impact factor: 7.446

10.  CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.

Authors:  Nicole F Liachko; Pamela J McMillan; Chris R Guthrie; Thomas D Bird; James B Leverenz; Brian C Kraemer
Journal:  Ann Neurol       Date:  2013-07-08       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.